These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 31980651)

  • 1. Targeting glutamine metabolism slows soft tissue sarcoma growth.
    Lee P; Malik D; Perkons N; Huangyang P; Khare S; Rhoades S; Gong YY; Burrows M; Finan JM; Nissim I; Gade TPF; Weljie AM; Simon MC
    Nat Commun; 2020 Jan; 11(1):498. PubMed ID: 31980651
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibiting glutaminase in acute myeloid leukemia: metabolic dependency of selected AML subtypes.
    Matre P; Velez J; Jacamo R; Qi Y; Su X; Cai T; Chan SM; Lodi A; Sweeney SR; Ma H; Davis RE; Baran N; Haferlach T; Su X; Flores ER; Gonzalez D; Konoplev S; Samudio I; DiNardo C; Majeti R; Schimmer AD; Li W; Wang T; Tiziani S; Konopleva M
    Oncotarget; 2016 Nov; 7(48):79722-79735. PubMed ID: 27806325
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The glutaminase inhibitor telaglenastat enhances the antitumor activity of signal transduction inhibitors everolimus and cabozantinib in models of renal cell carcinoma.
    Emberley E; Pan A; Chen J; Dang R; Gross M; Huang T; Li W; MacKinnon A; Singh D; Sotirovska N; Steggerda SM; Wang T; Parlati F
    PLoS One; 2021; 16(11):e0259241. PubMed ID: 34731180
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of the interactions of potent allosteric inhibitors with glutaminase C, a key enzyme in cancer cell glutamine metabolism.
    Huang Q; Stalnecker C; Zhang C; McDermott LA; Iyer P; O'Neill J; Reimer S; Cerione RA; Katt WP
    J Biol Chem; 2018 Mar; 293(10):3535-3545. PubMed ID: 29317493
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antitumor activity of the glutaminase inhibitor CB-839 in triple-negative breast cancer.
    Gross MI; Demo SD; Dennison JB; Chen L; Chernov-Rogan T; Goyal B; Janes JR; Laidig GJ; Lewis ER; Li J; Mackinnon AL; Parlati F; Rodriguez ML; Shwonek PJ; Sjogren EB; Stanton TF; Wang T; Yang J; Zhao F; Bennett MK
    Mol Cancer Ther; 2014 Apr; 13(4):890-901. PubMed ID: 24523301
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pyruvate anaplerosis is a mechanism of resistance to pharmacological glutaminase inhibition in triple-receptor negative breast cancer.
    Singleton DC; Dechaume AL; Murray PM; Katt WP; Baguley BC; Leung EY
    BMC Cancer; 2020 May; 20(1):470. PubMed ID: 32450839
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Glutaminase inhibitor CB-839 increases radiation sensitivity of lung tumor cells and human lung tumor xenografts in mice.
    Boysen G; Jamshidi-Parsian A; Davis MA; Siegel ER; Simecka CM; Kore RA; Dings RPM; Griffin RJ
    Int J Radiat Biol; 2019 Apr; 95(4):436-442. PubMed ID: 30557074
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A facile and sensitive method of quantifying glutaminase binding to its inhibitor CB-839 in tissues.
    Chen Y; Zhao Y; Bajor DL; Wang Z; Selfridge JE
    J Genet Genomics; 2020 Jul; 47(7):389-395. PubMed ID: 33004309
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glutaminase inhibition improves FLT3 inhibitor therapy for acute myeloid leukemia.
    Gregory MA; Nemkov T; Reisz JA; Zaberezhnyy V; Hansen KC; D'Alessandro A; DeGregori J
    Exp Hematol; 2018 Feb; 58():52-58. PubMed ID: 28947392
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dual inhibition of glutaminase and carnitine palmitoyltransferase decreases growth and migration of glutaminase inhibition-resistant triple-negative breast cancer cells.
    Reis LMD; Adamoski D; Ornitz Oliveira Souza R; Rodrigues Ascenção CF; Sousa de Oliveira KR; Corrêa-da-Silva F; Malta de Sá Patroni F; Meira Dias M; Consonni SR; Mendes de Moraes-Vieira PM; Silber AM; Dias SMG
    J Biol Chem; 2019 Jun; 294(24):9342-9357. PubMed ID: 31040181
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Glutamine metabolism via glutaminase 1 in autosomal-dominant polycystic kidney disease.
    Soomro I; Sun Y; Li Z; Diggs L; Hatzivassiliou G; Thomas AG; Rais R; Parker SJ; Slusher BS; Kimmelman AC; Somlo S; Skolnik EY
    Nephrol Dial Transplant; 2018 Aug; 33(8):1343-1353. PubMed ID: 29420817
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhancing the Efficacy of Glutamine Metabolism Inhibitors in Cancer Therapy.
    Yang WH; Qiu Y; Stamatatos O; Janowitz T; Lukey MJ
    Trends Cancer; 2021 Aug; 7(8):790-804. PubMed ID: 34020912
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of the MYC-Regulated Glutaminase Metabolic Axis Is an Effective Synthetic Lethal Approach for Treating Chemoresistant Ovarian Cancers.
    Shen YA; Hong J; Asaka R; Asaka S; Hsu FC; Suryo Rahmanto Y; Jung JG; Chen YW; Yen TT; Tomaszewski A; Zhang C; Attarwala N; DeMarzo AM; Davidson B; Chuang CM; Chen X; Gaillard S; Le A; Shih IM; Wang TL
    Cancer Res; 2020 Oct; 80(20):4514-4526. PubMed ID: 32859605
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeted Inhibition of EGFR and Glutaminase Induces Metabolic Crisis in EGFR Mutant Lung Cancer.
    Momcilovic M; Bailey ST; Lee JT; Fishbein MC; Magyar C; Braas D; Graeber T; Jackson NJ; Czernin J; Emberley E; Gross M; Janes J; Mackinnon A; Pan A; Rodriguez M; Works M; Zhang W; Parlati F; Demo S; Garon E; Krysan K; Walser TC; Dubinett SM; Sadeghi S; Christofk HR; Shackelford DB
    Cell Rep; 2017 Jan; 18(3):601-610. PubMed ID: 28099841
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting glutaminolysis has antileukemic activity in acute myeloid leukemia and synergizes with BCL-2 inhibition.
    Jacque N; Ronchetti AM; Larrue C; Meunier G; Birsen R; Willems L; Saland E; Decroocq J; Maciel TT; Lambert M; Poulain L; Hospital MA; Sujobert P; Joseph L; Chapuis N; Lacombe C; Moura IC; Demo S; Sarry JE; Recher C; Mayeux P; Tamburini J; Bouscary D
    Blood; 2015 Sep; 126(11):1346-56. PubMed ID: 26186940
    [TBL] [Abstract][Full Text] [Related]  

  • 16. GLS2 is protumorigenic in breast cancers.
    Dias MM; Adamoski D; Dos Reis LM; Ascenção CFR; de Oliveira KRS; Mafra ACP; da Silva Bastos AC; Quintero M; de G Cassago C; Ferreira IM; Fidelis CHV; Rocco SA; Bajgelman MC; Stine Z; Berindan-Neagoe I; Calin GA; Ambrosio ALB; Dias SMG
    Oncogene; 2020 Jan; 39(3):690-702. PubMed ID: 31541193
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Overview of the Development of Glutaminase Inhibitors: Achievements and Future Directions.
    Xu X; Meng Y; Li L; Xu P; Wang J; Li Z; Bian J
    J Med Chem; 2019 Feb; 62(3):1096-1115. PubMed ID: 30148361
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting glutamine metabolism improves sarcoma response to radiation therapy in vivo.
    Patel R; Cooper DE; Kadakia KT; Allen A; Duan L; Luo L; Williams NT; Liu X; Locasale JW; Kirsch DG
    Commun Biol; 2024 May; 7(1):608. PubMed ID: 38769385
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of Glucose Transporters and Glutaminase Synergistically Impairs Tumor Cell Growth.
    Reckzeh ES; Karageorgis G; Schwalfenberg M; Ceballos J; Nowacki J; Stroet MCM; Binici A; Knauer L; Brand S; Choidas A; Strohmann C; Ziegler S; Waldmann H
    Cell Chem Biol; 2019 Sep; 26(9):1214-1228.e25. PubMed ID: 31303578
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Glutaminase inhibition with telaglenastat (CB-839) improves treatment response in combination with ionizing radiation in head and neck squamous cell carcinoma models.
    Wicker CA; Hunt BG; Krishnan S; Aziz K; Parajuli S; Palackdharry S; Elaban WR; Wise-Draper TM; Mills GB; Waltz SE; Takiar V
    Cancer Lett; 2021 Apr; 502():180-188. PubMed ID: 33450358
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.